Dr. Jody Haigh is a full Professor in the Department of Pharmacology and Therapeutics at the University of Manitoba and Senior Scientist at CancerCare Manitoba Research Instittute. He completed his undergraduate degree in life sciences and Master of Science degree in Biochemistry at Queen’s University. This was followed by a PhD in Biochemistry at the IMP/University of Vienna, Austria. He spent four years as a postdoctoral fellow in the lab of Dr. Andras Nagy at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto. From 2004-2013 he was an Assistant Professor at Ghent University in Belgium and ran his own research group at the VIB. Dr. Haigh was then recruited to the Australian Centre for Blood Diseases (ACBD) at Monash University in Melbourne, Australia on a Larkin’s Fellowship as an Associate Professor. In July 2018, he returned home to Canada as an Associate Professor in the Department of Pharmacology and Therapeutics and has re-established his research group at the CancerCare Manitoba Research Institute. Throughout his career, he has developed and used novel mouse embryonic stem (ES) cell-based transgenic technologies to study genes involved in cardiovascular and hematopoietic development and disease related processes. He has co-authored numerous publications on the role of vascular endothelial growth factor signalling in organogenesis and disease processes including cancer. Over the last several years his group has started to work on understanding the role that the epithelial to mesenchymal transition (EMT) transcriptional modulators of the ZEB and SNAI family play in blood development and leukemia and leukemic stem cells. He has had a long-standing interest in the molecular basis of cellular (de) differentiation, cellular reprogramming, and cellular memory. He has co-authored 100 research articles in journals such as Blood, Cell Reports, Nature, Science Nature Medicine, Nature Cell Biology, and Nature Communications. His publications have been cited more than 8,400 times.